Patents Assigned to VAR2 PHARMACEUTICAL APS
  • IMMUNOTHERAPEUTIC TARGETING OF PLACENTAL-LIKE CHONDROITIN SULFATE USING CHIMERIC ANTIGEN RECEPTORS (CARS) AND IMMUNOTHERAPEUTIC TARGETING OF CANCER USING CARS WITH SPLIT-PROTEIN BINDING SYSTEMS
    Publication number: 20180298098
    Abstract: The present invention relates to polypeptides comprising conditionally active chimeric antigen receptor (CAR) and a split-protein binding system, a VAR2CSA polypeptide, or any other targeting agent. The present invention further relates to poly-peptides comprising VAR2CSA polypeptides or other targeting agent, and a split-protein binding system.
    Type: Application
    Filed: February 26, 2016
    Publication date: October 18, 2018
    Applicant: VAR2 Pharmaceutical ApS
    Inventor: Mai-Britt Zocca
  • TARGETING OF CHONDROITIN SULFATE GLYCANS
    Publication number: 20170081373
    Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).
    Type: Application
    Filed: October 5, 2016
    Publication date: March 23, 2017
    Applicant: VAR2 PHARMACEUTICAL APS
    Inventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
  • TARGETING OF CHONDROITIN SULFATE GLYCANS
    Publication number: 20170016905
    Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).
    Type: Application
    Filed: October 5, 2016
    Publication date: January 19, 2017
    Applicant: VAR2 PHARMACEUTICAL APS
    Inventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen